We wish we’d written that: STAT staffers share their favorite stories of 2019
It’s been a busy year at STAT, but we still have found the time to see what other journalists are writing — and get jealous we didn’t do it ourselves.
Related Articles
Are you affected by the Trump administration’s pause on health communications, science meetings, and reviews?
Have you been affected by the Trump administration’s pause on communications, science meetings, and reviews? @statnews would like to hear from you.
Pfizer to pay $60 million to settle claims that Biohaven paid kickbacks to doctors
The alleged violations occurred before Pfizer bought Biohaven and its migraine treatment three years ago for $11.6 billion.
Trump’s restrictions spark chaos across health and science agencies
The Trump administration’s freeze on communications, travel, and diversity efforts has sowed chaos across federal health agencies.
Veteran researcher who was critical of U.S. response to Covid named acting NIH head
The Trump administration has appointed Matthew Memoli, a veteran researcher who was critical of the U.S. response to the Covid pandemic, as acting head of…
Pfizer to pay $60 million to settle claims that Biohaven paid kickbacks to doctors
The alleged violations occurred before Pfizer bought Biohaven and its migraine treatment three years ago for $11.6 billion.
Trump’s restrictions spark chaos across health and science agencies
The Trump administration’s freeze on communications, travel, and diversity efforts has sowed chaos across federal health agencies.
Veteran researcher who was critical of U.S. response to Covid named acting NIH head
The Trump administration has appointed Matthew Memoli, a veteran researcher who was critical of the U.S. response to the Covid pandemic, as acting head of…
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
CMS withdraws appeal of UnitedHealth Medicare Advantage star ratings case
The decision comes as Trump paused some federal work and could help UnitedHealth generate bigger profits from the taxpayer-funded program.
Novo Nordisk’s next-generation obesity treatment shows promise in early study
A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the competitive field.